Avoiding No Man's Land: Potential Unintended Consequences of Follow-On Biologics


Still, the essential debate encompasses two broad issues: patient safety and industry economics. This paper from Deloitte explores what will constitute threshold biosimilarity? The definition of biosimilarity is likely to involve standards regarding the degree to which a follow-on biologic has the same mechanism of action (i.e., if it targets the same molecular disease regulator) as the original drug, and if it passes efficacy and safety screens.

Author: Deloitte

Find more white papers on Drug DeliveryDrug Delivery

View all white papers»